Table 3. Age quartiles and PSA ranges in relation to ERG status and clinicopathological features.
| A. Age quartiles (years) |
1. (35–55) |
2. (56–61) |
3. (62–66) |
4. (67–82) |
1. (35–55) |
2. (56–61) |
3. (62–66) |
4. (67–82) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERG status | − | + | − | + | − | + | − | + | ||||
| Median |
% Differences (ERG+ to ERG−) |
|||||||||||
| %TV, % | 3.4 | 2.6 | 3.5 | 3.3 | 2.9 | 4.2 | 2.9 | 4.2 | −23 | −4 | 45 | 44* |
| TV, ml | 1.2 | 0.9 | 1.3 | 1.4 | 1.3 | 1.6 | 1.3 | 1.6 | −25 | 2 | 22 | 20* |
| PSA diagnostic for biopsy, ng ml−1 | 4.1 | 3.1 | 5.4 | 4.9 | 5.5 | 5.5 | 6.4 | 6.2 | −24* | −10 | 2 | −3 |
| fPSA%, % | 14 | 12 | 12 | 12 | 14 | 14 | 15 | 15 | −17* | 2 | −2 | 5 |
| PV, ml | 35 | 34 | 36 | 35 | 45 | 40 | 45 | 40 | −3* | −3 | −11 | −11 |
| PSA density, ng ml−2 | 0.11 | 0.09 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.15 | −18 | −9 | 13 | 7 |
| B. PSA ranges (ng ml−1) |
1 (<4) |
2 (4– 10) |
3 (⩾10) |
1 (<4) |
2 (4–10) |
3 (⩾10) |
|||
|---|---|---|---|---|---|---|---|---|---|
| ERG status | − | + | − | + | − | + | |||
| Median |
% Differences (ERG+ to ERG−) |
||||||||
| %TV, % | 2.3 | 2.3 | 3.0 | 3.1 | 6.7 | 18.5 | 0 | 3 | 176* |
| TV, ml | 0.9 | 0.8 | 1.3 | 1.4 | 2.4 | 9.3 | −11 | 8 | 288* |
| PSA diagnostic for biopsy, ng ml−1 | 3.0 | 2.8 | 6.0 | 5.8 | 13.7 | 13.9 | −7* | −3 | 1 |
| fPSA%, % | 16.0 | 12.6 | 14.0 | 12.7 | 9.9 | 16.2 | −21* | −9* | 64 |
| PV, ml | 40 | 35 | 50 | 43 | 35 | 50 | −13* | −14* | 43* |
| PSA density, ng ml−2 | 0.08 | 0.08 | 0.1 | 0.1 | 0.3 | 0.3 | 0 | 0 | 0 |
Abbreviations: PV, prostate volume; TV, tumor volume.
*P<0.05